ZEN-3694 in combination with "enzalutamide" in patients with metastatic castration resistant prostate cancer (mCRPC)

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

ZEN-3694 in combination with "enzalutamide" in patients with metastatic castration resistant prostate cancer (mCRPC)

posted on Aug 27, 2021 12:56PM

To our scientists:

NASDAQ : EPIX: Unwarranted Selloff Following Phase 1 Trial Update

https://scr.zacks.com/news/news-details/2021/EPIX-Unwarranted-Selloff-Following-Phase-1-Trial-Update/default.aspx

How does Zenith's, ZEN-3694 compare with ESSA Pharma Inc., EPI-7386?

https://www.zenithepigenetics.com/programs/pipeline/prostate-cancer

Koo

2 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply